InterDigital Expects $1 Billion in Annual Recurring Revenue by 2030-January 2024-www.financetom.com

InterDigital Expects $1 Billion in Annual Recurring Revenue by 2030

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

InterDigital Expects $1 Billion in Annual Recurring Revenue by 2030

Sep 16, 2024 12:38 PM

09:10 AM EDT, 09/16/2024 (MT Newswires) -- InterDigital (IDCC) said Monday it expects $1 billion in annual recurring revenue by 2030.

The company also anticipates $600 million in adjusted earnings before interest, taxes, depreciation, and amortization by 2030, it added.

Price: 136.00, Change: +0.01, Percent Change: +0.01

Previous page： Nuvectis Pharma Q3 net loss widens Next page： Wingstop Q3 system-wide sales rise 10%, helped by new restaurants

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Nuvectis Pharma Q3 net loss widens

Nov 4, 2025

Overview * Nuvectis Q3 net loss widens to $7.5 mln, driven by milestone and study costs * Cash position improves to $35.4 mln, supported by public offering and ATM facility * NXP900 Phase 1b program initiated, showcasing therapeutic potential in advanced cancers Outlook * Cash runway expected to support operations into 3Q-2027 Result Drivers * Research and development expenses were...

Wingstop Q3 system-wide sales rise 10%, helped by new restaurants

Nov 4, 2025

Overview * Wingstop ( WING ) fiscal Q3 system-wide sales rise 10% to $1.4 bln * Adjusted EBITDA for fiscal Q3 grows 18.6% to $63.7 mln, highest quarter on record * Company opened 114 net new restaurants, achieving 19.3% net new unit growth Outlook * Wingstop ( WING ) revises 2025 domestic same store sales growth to decline 3%-4% *...

Hillman Q3 net sales rise 8%, beat estimates

Nov 4, 2025

Overview * Hillman Q3 2025 net sales rise 8% to record $424.9 mln, beating analyst expectations * Adjusted EPS for Q3 2025 beats consensus, reaching $0.22 per share * Company repurchased 325.6 thousand shares, totaling $3.2 mln Outlook * Hillman maintains FY 2025 net sales guidance at $1.535 to $1.575 bln * Company raises FY 2025 adjusted EBITDA guidance to...

BRIEF-Evoke Pharma Enters Into Definitive Agreement To Be Acquired By QOL Medical

Nov 4, 2025

Nov 4 (Reuters) - Evoke Pharma Inc ( EVOK ): * EVOKE PHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY QOL MEDICAL * EVOKE PHARMA INC ( EVOK ): PROPOSED DEAL FOR FOR $11.00 PER SHARE IN CASH AT CLOSING Source text: Further company coverage: ...